Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Heinz Liesenfeld"'
Autor:
Michael Desch, Christina Schlecker, Kathrin Hohl, Karl-Heinz Liesenfeld, Tom Chan, Fabian Müller, Glen Wunderlich, Sascha Keller, Naoki Ishiguro, Sven Wind
Publikováno v:
Journal of Clinical Psychopharmacology. 43:113-121
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13afb697e0fb91e5005bbdc2c107d546
https://doi.org/10.1097/jcp.0000000000001656
https://doi.org/10.1097/jcp.0000000000001656
Autor:
Alan Menter, Stanley Cohen, Jonathan Kay, Vibeke Strand, Alice Gottlieb, Stephen Hanauer, Sravan Kumar Eduru, Susanne Buschke, Benjamin Lang, Karl-Heinz Liesenfeld, Jennifer Schaible, Dorothy McCabe
Publikováno v:
American Journal of Clinical Dermatology. 23:719-728
BI 695501 is an FDA-approved biosimilar to adalimumab reference product (RP). VOLTAIRE-X was a randomized clinical trial to assess outcomes with a biosimilar monoclonal antibody in line with the FDA requirements for designation as an 'interchangeable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::642a1dc5978b517337d8795a946f768a
https://doi.org/10.1007/s40257-022-00708-w
https://doi.org/10.1007/s40257-022-00708-w
Autor:
Curtis K. Johnston, Rena J. Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M. Riggs, Karl-Heinz Liesenfeld
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 485 (2021)
In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evalua
Externí odkaz:
https://doaj.org/article/dd6fa398c90b42af977a48e99f495ba1
Autor:
Sven Wind, Tom S. Chan, Regina Sennewald, Karl-Heinz Liesenfeld, Holger Rosenbrock, Glen Wunderlich, Michael Desch, Sascha Keller, Jasmin Link, Sophia Goetz, Markus Goettel
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objective Increased glycine availability at the synaptic cleft may enhance N-methyl-D-aspartate receptor signalling and provide a promising therapeutic strategy for cognitive impairment associated with schizophrenia. These studies aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb61f0cdf7d39d5f56cb50b6986a3f57
http://europepmc.org/articles/PMC8752533
http://europepmc.org/articles/PMC8752533
Autor:
Luisa Sievers, Michael Huss, Halgard Schmidt-Kittler, Tim Külzer, Saskia Dalm, Esther Sobanski, Heinz Liesenfeld
Publikováno v:
Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie. 49:307-311
Abstract. Seeds of the Hawaiian Baby Woodrose (HBWR, Argyreia nervosa) are known as “legal or herbal highs” and can be easily purchased online in Germany. They contain various ergot alkaloids, including lysergic acid amide (LSA), which is chemica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024f8ba8ae34f50970af485e30d256c9
https://doi.org/10.1024/1422-4917/a000792
https://doi.org/10.1024/1422-4917/a000792
Autor:
Karl-Heinz Liesenfeld, John Mondick, William Knebel, Jia Kang, Rena J. Eudy-Byrne, Girish Jayadeva
Publikováno v:
British Journal of Clinical Pharmacology
Aims Adalimumab-adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.). The key objectives of this study were using a population pharmacokinetic (PPK) approach to assess pharmacokinetic (PK) similarity between ada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a439f0509498a490010971c1a6ac90be
https://doi.org/10.1111/bcp.14330
https://doi.org/10.1111/bcp.14330
Autor:
Matthew M. Riggs, Julio Rosenstock, Lori M. Laffel, Rena J. Eudy-Byrne, Ahmed Elmokadem, Jan Marquard, Bruce A. Perkins, Nima Soleymanlou, Valerie Nock, Dietmar Neubacher, Curtis K. Johnston, Karl Heinz Liesenfeld, Jay S. Skyler, Jyothis T. George
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To confirm the observed reduction in HbA1c for the 2.5 mg dose in EASE‐3 by modelling and simulation analyses. Materials and methods Independent of data from EASE‐3 that tested 2.5 mg, we simulated the effect of a 2.5 mg dose through patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00156de9e54d639a6362625fbc0b0cf0
https://doi.org/10.1111/dom.13945
https://doi.org/10.1111/dom.13945
Autor:
Karl-Heinz Liesenfeld, Nima Soleymanlou, Valerie Nock, Jan Marquard, Ahmed Elmokadem, Curtis K. Johnston, Rena J. Eudy-Byrne, Matthew M. Riggs
Publikováno v:
Pharmaceutics
Volume 13
Issue 4
Pharmaceutics, Vol 13, Iss 485, p 485 (2021)
Volume 13
Issue 4
Pharmaceutics, Vol 13, Iss 485, p 485 (2021)
In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80641c0d959c67f57b9c63169c696e4a
Autor:
Michael Desch, Bernhard Schmid, Riccardo Giovannini, Viktoria Moschetti, Glen Wunderlich, Christina Schlecker, Karl-Heinz Liesenfeld, Sascha Keller, Sophia Goetz, Cornelia Dorner-Ciossek, Sven Wind, Oliver Kleiner, Steven Ramael, Gwenaëlle Fillon, Holger Rosenbrock
Publikováno v:
Clinical and Translational Science
BI 425809 is a potent and selective glycine transporter 1 (GlyT1) inhibitor being developed for the treatment of cognitive impairment in Alzheimer disease and schizophrenia. Translational studies evaluated the effects of BI 425809 on glycine levels i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feadccd75c538a282afb4f73b40a0f02
https://doi.org/10.1111/cts.12578
https://doi.org/10.1111/cts.12578
Autor:
Armin Schultz, Sophia Goetz, Karl-Heinz Liesenfeld, Christina Schlecker, Michael Desch, Holger Schmitt, Viktoria Moschetti, Glen Wunderlich, Sven Wind
Publikováno v:
Clinical Drug Investigation
Background and Objective Schizophrenia and Alzheimer’s disease are characterised by abnormalities in glutamatergic pathways related to N-methyl-d-aspartate receptor hypofunction. Glycine is an N-methyl-d-aspartate receptor co-agonist; inhibition of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff2ecf545edb1ee14c2574ef5ab68c9
https://doi.org/10.1007/s40261-018-0660-2
https://doi.org/10.1007/s40261-018-0660-2